OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Woyach on the Role of Chemoimmunotherapy in CLL

August 11th 2020

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Burris on Treatment Considerations in TNBC

August 11th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​treatment considerations in triple-negative breast cancer.

Dr. Monk on Emerging Therapies in Cervical Cancer

August 11th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses emerging therapies in cervical cancer.

Dr. Khong on the Potential Benefit of IO/Endocrine Therapy in ER+ Breast Cancer

August 11th 2020

Hung Khong, MD, discusses the potential benefit of combining immunotherapy with endocrine therapy in estrogen receptor–positive, HER2-negative breast cancer.

Dr. O'Donnell Discusses Ongoing Research Efforts in Multiple Myeloma

August 11th 2020

Betsy O'Donnell, MD, discusses ongoing research efforts in multiple myeloma.

Dr. Tykodi on the KEYNOTE-427 Trial With Pembrolizumab in RCC

August 11th 2020

Scott S. Tykodi, MD, PhD, provides background to the phase 2 KEYNOTE-427 trial with pembrolizumab in renal cell carcinoma.

Dr. Abraham on Key Considerations in the Management of TGCT

August 11th 2020

John A. Abraham, MD, FACS, discusses key considerations regarding the management of tenosynovial giant cell tumor.

Dr. Mehta on the Evolution of Treatment in Gastric and GEJ Cancers

August 11th 2020

Rutika J. Mehta, MD, MPH, discusses how treatment has evolved in recent years for gastric and gastroesophageal junction cancers.

Dr. Jacobson on the Interim Analysis of the MZL Cohort in the ZUMA-5 Trial

August 11th 2020

Caron Jacobson, MD, discusses the interim analysis results of the marginal zone lymphoma cohort in the phase 2 ZUMA-5 study with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Davids on Remaining Questions With Umbralisib/Ibrutinib in CLL and MCL

August 10th 2020

Matthew S. Davids, MD, MMSc, discusses ​remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.

Dr. Ghia on Lack of OS Advantage With Acalabrutinib Per ASCEND Trial in CLL

August 10th 2020

Paolo Ghia, MD, PhD, discusses overall survival data with acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia in the phase 3 ASCEND trial.

Dr. Tripathy on Trastuzumab Deruxtecan Versus T-DM1 in HER2-Expressing Breast Cancers

August 10th 2020

Debu Tripathy, MD, discusses fam-trastuzumab deruxtecan-nxki versus ado-trastuzumab emtansine in HER2-expressing breast cancers.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10th 2020

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Recent Advances in Melanoma

August 10th 2020

Grace Cherry, RN, ​MSN, NP, discusses ​recent advances in melanoma. 

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

August 10th 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Ahmed on the Role of Multidisciplinary Care in Breast Cancer Brain Metastases

August 10th 2020

Kamran A. Ahmed, MD, discusses the role of multidisciplinary care in breast cancer–related brain metastases.

Dr. VanderWalde on Personalizing Therapy in Rectal Cancer

August 10th 2020

Noam VanderWalde, MD, MS, discusses the push toward personalizing therapy in rectal cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

Dr. Burris on Predictive Biomarkers for Chemoimmunotherapy in TNBC

August 7th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses using biomarkers to determine the benefits of immunotherapy and chemotherapy in triple-negative breast cancer.

Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC

August 7th 2020

Jennifer L. Atlas, MD, discusses the rationale for using cemiplimab-rwlc as a first intervention for patients with locally advanced cutaneous squamous cell carcinoma.

NEXT PAGE
PREVIOUS PAGE